Upload
ronald-baldwin
View
222
Download
4
Embed Size (px)
Citation preview
SGLT-2 Inhibitors
A New Modality for Treating Type 2 Diabetes
David Joffe BSPharm, CDE, Clinical Assistant Professor of Pharmacotherapy and Translational Research Courtney Glanzrock, PharmD Candidate University of Florida College of Pharmacy
Two sodium glucose transporters, cause glucose reabsorption, have been identified: SGLT-1 and SGLT-2
SGLT-2 is found only in the proximal tubule of the kidney, accounts for 90% of the re-absorption of glucose
SGLT-1 is found in the gut and other tissues, account for approximately 10% of glucose reabsorption
SGLT-1 and SGLT-2
Invokana (Canagliflozin) 1st SGLT-2 inhibitor, approved March 2013
Once daily dosing before 1st meal of day, 100mg or 300mg tablets
MOA: Inhibition of SGLT2 reduces reabsorption of glucose in the kidney, resulting in increased urinary glucose excretion, with a consequent lowering of plasma glucose levels as well as weight loss.
Blocks approximately 50-80 grams of glucose per day from being reabsorbed
SGLT-2 Inhibitor - Canagliflozin
SGLT2-I
Positive effects: Reduction in body weight and systolic blood pressure
Side effects: Most common: Vaginal yeast infection, urinary tract infection and increased urination. Hypoglycemia (<5%), dehydration, dizziness or fainting, hyperkalemia
Contraindications: Clinicians should not use canagliflozin to treat patients with type 1 diabetes, patients with type 2 diabetes who have increased ketones in their blood or urine, severe renal impairment, end-stage renal disease or patients receiving dialysis
SGLT-2 Inhibitor-Canagliflozin
SGLT-2 InhibitorFirst In Class
Canagliflozin Side Effects
http://www.invokanahcp.com/safety-information/safety-and-tolerability-profile?utm_source=google&utm_medium=cpc&utm_campaign=Invokana+HCP&utm_term=canagliflozin%20side%20effects&utm_content=Side+Effects+-+Exact|mkwid|suZUJen2m|pcrid|24016786155
Drug Interactions:1.UGT Inducers (Rifampin, Phenytoin,
Phenobarbitol, Ritonavir)- Decreased canagliflozin, consider increasing dose of canagliflozin
2.Digoxin- Increased digoxin concentration, monitor levels
Pregnancy Category C Do Not Use: GFR <30mL/min, end stage renal
disease, or patients on dialysis
Canagliflozin
Pre-Marketing Study Results: Average decrease in A1C levels 1%Weight Loss average 5-10 poundsDecrease in systolic blood pressure
approximately 4%Increase HDL approximately 7.6% Increase LDL approximately 11.7%Low risk of hypoglycemia
SGLT-2 Inhibitor-Canagliflozin
Pipeline:1.Empagliglozin (Eli Lilly/Behringer)2.Dapagliflozin (AstraZeneca)3.Remogliflozin Etabonate (GlaxoSmithKline)4.Sergliflozin Etabonate (GlaxoSmithKline)5.Tofoglitazone (Roche & Chugal)
SGLT-2 Inhibitors
Medication Average A1C lowering
Hypoglycemic Agent
Weight Gain/Loss
Metformin 1.5% No Loss
Sulfonylureas 1.5% Yes Gain
Glinides 1-1.5% No Gain
SGLT-2 Inhibitors
1% No Loss
TZDs 0.5-1.4% No Gain
α-Glucosidase Inhibitor
0.5-0.8% No Neutral
DPP-4 Inhibitors
0.5-1% No Neutral
Comparing Agents
Berkrot, Bill. "Johnson & Johnson Diabetes Drug Tops Older Therapies in Studies." Reuters. Thomson Reuters, 09 June 2012. Web. 02 Apr. 2013.
"Canagliflozin Provided Substantial and Sustained Glycemic Improvements as Monotherapy and in Add-On Combinations in Adults with Type 2 Diabetes in Five Phase 3 Studies." Johnson & Johnson. Jansen Research & Development, 09 June 2012. Web. 02 Apr. 2013.
Clarke, Toni. "FDA Approves Johnson & Johnson Diabetes Drug, Canagliflozin." Reuters. Thomson Reuters, 29 Mar. 2013. Web. 01 Apr. 2013.
"Diabetes Treatment, Part 2: Oral Agents for Glycemic Management." Clinical Diabetes. N.p., Oct. 2007. Web. 12 Apr. 2013.
FDA Approves Invokana to Treat Type 2 Diabetes. N.p., n.d. Web. 01 Apr. 2013
"Invokana." INVOKANA™ (Canagliflozin) Treatment for Type 2 Diabetes. N.p., n.d. Web. 12 Apr. 2013
Nainggolan, Lisa. "FDA Approves Canagliflozin, a First-in-Class Diabetes Drug." Medscape Log In. N.p., 29 Mar. 2013. Web. 01 Apr. 2013.
References